[关键词]
[摘要]
目的 探索痰热清胶囊治疗新型冠状病毒肺炎(COVID-19)的网络调控机制。方法 选取痰热清胶囊中19个主要成分为研究对象,利用Swiss Target Prediction服务器和TCMSP数据库预测化合物潜在作用靶点,借助Omicsbean分析系统与String 10数据库对靶点进行基因本体(gene ontology,GO)功能富集分析和信号通路分析,利用Cytoscape 3.6.1软件进行可视化处理。结果 19个化合物可通过作用于163个相关靶点干预68条关键信号通路,如白细胞介素-17(IL-17)信号通路、T细胞受体信号通路、花生四烯酸代谢、cAMP信号通路、PI3K-Akt信号通路、甲型流感等,主要涉及抗炎、免疫调节、解热、化痰、镇咳平喘、止痛、抗菌、抗病毒、镇静等方面,构建了痰热清胶囊"化合物-靶点-通路-药理作用-功效"网络。结论 痰热清胶囊中主要化学成分野黄芩苷、黄芩苷、千层纸素-7-O-葡萄糖醛酸苷、白杨素-7-O-葡萄糖醛酸苷、连翘苷、连翘酯苷E、连翘酯苷D、绿原酸、咖啡酸、异绿原酸A、熊去氧胆酸、鹅去氧胆酸等可能通过作用于TNF、EGFR、NOS3、PTGS2、IL2、GABBR1、MAPK14、ADRB2、REN、VCAM1、ACHE、PTPRC等关键蛋白干预了多个与清热、化痰、解毒相关的生物过程,从而发挥对COVID-19的治疗作用。
[Key word]
[Abstract]
Objective To explore the network regulation mechanism of Tanreqing Capsule (TRQC) on the treatment of coronavirus disease 2019 (COVID-19). Methods Potential targets of the 19 major constituents in TRQC were predicted by the Swiss Target Prediction server and TCMSP database. Gene ontology (GO) function enrichment and pathway analysis of the targets were analyzed by Omicsbean analytic system and String 10 database. Finally, Cytoscape 3.6.1 software was used to construct the network pharmacology map. Results A total of 19 compounds affected 68 pathways such as IL-17 signaling pathway, T cell receptor signaling pathway, arachidonic acid metabolism, cAMP signaling pathway, PI3K-Akt signaling pathway, influenza A, etc, by acting on 163 related targets, which associated with anti-inflammation, immune regulation, antipyresis, eliminating phlegm, relieving cough and asthma, analgesia, antibacterial and antiviral, and sedation. The network of "compound-target-pathway-pharmacological action-efficacy" was also constructed. Conclusion The major constituents in TRQC, including scutellarin, baicalin, oroxylin-7-O-glucuronide, chrysin-7-O-glucuronide, forsythin, forsythiaside E, forsythiaside D, chlorogenic acid, caffeic acid, isochlorogenic acid A, ursodeoxycholic acid and chenodeoxycholic acid, may interfere with efficacy-related biological processes associated with antipyresis, eliminating phlegm and removing toxin by acting on key protein like TNF, EGFR, NOS3, PTGS2, IL2, GABBR1, MAPK14, ADRB2, REN, VCAM1, ACHE, PTPRC, etc.
[中图分类号]
R285.5
[基金项目]